NERV - Minerva Neurosciences, Inc.
| Previous Close | 7.21 |
| Open | 7.17 |
| Bid | 7.29 x 800 |
| Ask | 7.34 x 800 |
| Day's Range | 7.17 - 7.48 |
| 52 Week Range | 5.00 - 12.95 |
| Volume | 45,372 |
| Avg. Volume | 158,970 |
| Market Cap | 281.041M |
| Beta (3Y Monthly) | 2.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.95 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.00 |
- Simply Wall St.•28 days ago
How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own?
Every investor in Minerva Neurosciences, Inc. (NASDAQ:NERV) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...
- GlobeNewswire•2 months ago
Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
“In addition to providing further significant intellectual property protection for MIN-117, the pre-clinical data supporting the application suggest that this compound should be investigated beyond mood and anxiety disorders to include chronic pain, which is often a symptom of several neuro-psychiatric disorders,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “Chronic pain is also one of the main reasons cited by patients with MDD who seek medical help,” said Dr. Luthringer.
- GlobeNewswire•2 months ago
Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018
WALTHAM, Mass., Nov. 21, 2018 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to.
- GlobeNewswire•2 months ago
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256.
- Zacks•2 months ago
Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy?
Minerva Neurosciences has been struggling lately, but the selling pressure may be coming to an end soon.
- GlobeNewswire•2 months ago
Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a roluperidone update and key opinion leader event on Tuesday, November 20, 2018 beginning at 8:00 a.m. Eastern Time in New York. Members of Minerva’s senior management will be joined by an expert key opinion leader.
- GlobeNewswire•2 months ago
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018
WALTHAM, Mass., Nov. 07, 2018 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of NERV earnings conference call or presentation 5-Nov-18 1:30pm GMT
Q3 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•2 months ago
Minerva Neurosciences: 3Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 31 cents. Minerva Neurosciences shares have risen 93 percent since the beginning of the year. The stock has increased ...
- Simply Wall St.•3 months ago
Minerva Neurosciences Inc (NASDAQ:NERV): Risks You Need To Consider Before Buying
If you own shares in Minerva Neurosciences Inc (NASDAQ:NERV) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- Zacks•4 months ago
J&J Submits NDA to the FDA for Depression Drug in Adults
Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.
- Benzinga•5 months ago
The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 22) Acer Therapeutics Inc (NASDAQ: ACER ) Avanos Medical Inc (NYSE: ...
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of NERV earnings conference call or presentation 2-Aug-18 12:30pm GMT
Q2 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•6 months ago
Minerva Neurosciences: 2Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 32 cents per share. Minerva Neurosciences shares have climbed 32 percent since the beginning of the year. The stock has increased 13 percent ...
- GlobeNewswire•6 months ago
Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
Management to host conference call WALTHAM, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of ...
- GlobeNewswire•6 months ago
Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel
WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...
